{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825894727258368.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1136/ard.62.7.686"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S000349672408960X?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S000349672408960X?httpAccept=text/plain"}},{"identifier":{"@type":"URI","@value":"https://syndication.highwire.org/content/doi/10.1136/ard.62.7.686"}}],"dc:title":[{"@value":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380567003960719115","@type":"Researcher","foaf:name":[{"@value":"P Ostuni"}]},{"@id":"https://cir.nii.ac.jp/crid/1380584750255095939","@type":"Researcher","foaf:name":[{"@value":"C Botsios"}]},{"@id":"https://cir.nii.ac.jp/crid/1380584750255095938","@type":"Researcher","foaf:name":[{"@value":"L Punzi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380584750255095936","@type":"Researcher","foaf:name":[{"@value":"P Sfriso"}]},{"@id":"https://cir.nii.ac.jp/crid/1380584750255095937","@type":"Researcher","foaf:name":[{"@value":"S Todesco"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00034967"}],"prism:publicationName":[{"@value":"Annals of the Rheumatic Diseases"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2003-07","prism:volume":"62","prism:number":"7","prism:startingPage":"686","prism:endingPage":"687"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S000349672408960X?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S000349672408960X?httpAccept=text/plain"},{"@id":"https://syndication.highwire.org/content/doi/10.1136/ard.62.7.686"}],"createdAt":"2003-06-16","modifiedAt":"2025-01-18","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1390282679753835520","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"関節リウマチに用いる生物学的製剤による重篤な感染症の解析"},{"@language":"en","@value":"Signal Detection of Serious Infections Following Treatment with Biologics for Rheumatoid Arthritis:"}]},{"@id":"https://cir.nii.ac.jp/crid/2050870367073795072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1136/ard.62.7.686"},{"@type":"CROSSREF","@value":"10.1007/s10157-011-0464-7_references_DOI_1IGxnbBO1JONvSe3sGWFqbQd95i"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.40.586_references_DOI_1IGxnbBO1JONvSe3sGWFqbQd95i"}]}